Gaudium IVF Adopts Code for Fair Disclosure of UPSI
Gaudium IVF and Women Health Limited has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). Approved on November 4, 2024, the code ensures timely and transparent disclosure of material information to stakeholders and outlines procedures for handling UPSI.
This is a standard regulatory compliance measure and does not involve any new business initiatives, financial results, or corporate actions that would significantly impact the company's operations or stock performance.
The announcement is a routine compliance filing regarding the adoption of a code for fair disclosure of UPSI, as required by SEBI regulations. It does not contain any new business developments or financial information that would positively or negatively impact the company.
Gaudium IVF and Women Health Limited has formally adopted and submitted its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). This code, framed in accordance with Regulation 8(1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, ensures timely and adequate disclosure of UPSI to stakeholders, maintaining transparency and preventing misuse.
The company's board of directors approved the code on November 4, 2024. The code outlines the company's commitment to prompt and uniform dissemination of UPSI, designating a Chief Investor Relations Officer to manage disclosures. It also details procedures for responding to market rumors and ensures that information shared with analysts is not UPSI.
Furthermore, the policy includes provisions for sharing UPSI for legitimate purposes in the ordinary course of business, such as with partners, collaborators, lenders, and advisors. A structured digital database will be maintained to track the sharing of UPSI, with records preserved for at least eight years. The company will also establish inquiry procedures in case of suspected leakage of UPSI.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under corporate governance report. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.